Birmingham Vivo Bioscience announced entering an R&D collaboration for development of cell-based assays for the xCELLigence System, co-developed by Roche-ACEA and marketed by Roche Applied Science. Details here. The B'ham BJ says the deal is worth about $2MM now for Vivo.
Friday, October 29, 2010
B'ham Vivo BioScience in Roche-ACEA pact
Birmingham Vivo Bioscience announced entering an R&D collaboration for development of cell-based assays for the xCELLigence System, co-developed by Roche-ACEA and marketed by Roche Applied Science. Details here. The B'ham BJ says the deal is worth about $2MM now for Vivo.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment